Mibefradil
Mibefradil
Mibefradil (pronounced mi-be-fra-dil) is a pharmacological agent that was formerly marketed as a T-type calcium channel blocker. It was withdrawn from the market due to potential drug interactions.
Etymology
The term "Mibefradil" is derived from the chemical structure of the drug. The "Mi" stands for methyl, "be" for benzene, "fra" for fragment, and "dil" for dihydropyridine, which is a class of calcium channel blockers.
Pharmacology
Mibefradil is a T-type calcium channel blocker, which means it inhibits the entry of calcium ions into cardiac muscle and smooth muscle cells. This action can lead to a decrease in muscle contraction, which can help to lower blood pressure and reduce the workload on the heart.
Clinical Use
Mibefradil was initially approved for the treatment of hypertension and angina pectoris, a type of chest pain caused by reduced blood flow to the heart. However, it was withdrawn from the market due to potential drug interactions.
Related Terms
See Also
External links
- Medical encyclopedia article on Mibefradil
- Wikipedia's article - Mibefradil
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski